EMG
BIO icon

Ellington Management Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Ellington Management Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-700
Closed -$219K – 599
2019
Q2 		$219K Buy
+700
New +$210K 0.04% 458
2017
Q3 		– Sell
-2,100
Closed -$475K – 643
2017
Q2 		$475K Buy
+2,100
New +$458K 0.07% 254
2016
Q1 		– Sell
-2,900
Closed -$402K – 507
2015
Q4 		$402K Buy
+2,900
New +$402K 0.14% 195
2014
Q2 		– Sell
-3,700
Closed -$474K – 455
2014
Q1 		$474K Buy
+3,700
New +$474K 0.14% 228

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Ellington Management Group's BIO Position: Q3 2019 in Review

Ellington Management Group sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2019, closing a stake of 700 shares — an estimated $219K sold.

Ellington Management Group first reported a position in BIO in Q1 2014 and held it in 4 quarters. The position peaked at $475K in Q2 2017. 355 funds tracked by Wall St. Rank hold BIO as of Q3 2019.

  • Ellington Management Group reported no remaining Bio-Rad Laboratories Class A position as of Q3 2019 after selling out during the quarter.
  • Ellington Management Group sold 700 Bio-Rad Laboratories Class A shares in Q3 2019, an estimated $219K.
  • Ellington Management Group first reported a position in Bio-Rad Laboratories Class A in Q1 2014 and held it in 4 quarters.
  • Ellington Management Group's Bio-Rad Laboratories Class A position peaked at $475K in Q2 2017.
  • 355 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2019.

Based on Ellington Management Group's 13F filing for Q3 2019, filed 14 Nov 2019.